表紙
市場調查報告書

人類乳突病毒(HPV)治療藥的全球市場:2019年∼2023年

Global Human Papillomavirus (HPV) Therapeutics Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 785653
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
Back to Top
人類乳突病毒(HPV)治療藥的全球市場:2019年∼2023年 Global Human Papillomavirus (HPV) Therapeutics Market 2019-2023
出版日期: 2019年01月28日內容資訊: 英文 113 Pages
簡介

診斷技術的進步促進市場成長。現在市場上可利用的診斷方法有子宮頸抹片檢查,陰道鏡,HPV DNA檢驗。全球人類乳突病毒(HPV)治療藥市場預測至2023年將以9%的年複合成長率 (CAGR) 擴大。

本報告提供全球人類乳突病毒(HPV)治療藥市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的供應商簡介等相關資訊彙整。

第1章 摘要整理

第2章 報告的範圍

第3章 市場情況

  • 市場生態系統
  • 市場特長
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模:2018年
  • 市場規模與預測:2018∼2023年

第5章 波特的五力分析

第6章 各給藥途徑市場區隔

  • 市場區隔
  • 比較
  • 非口服
  • 局部
  • 市場機會

第7章 客戶趨勢

第8章 各地區趨勢

  • 各地區市場區隔
  • 比較
  • 北美
  • 歐洲
  • 亞洲
  • 其他
  • 主要國家
  • 市場機會

第9章 促進要素與課題

第10章 市場趨勢

第11章 供應商環境

第12章 供應商分析

  • 被網羅的供應商
  • 供應商分類
  • 市場定位
  • ALLERGAN
  • Bausch Health
  • GlaxoSmithKline plc.
  • Lee's Pharmaceutical Holdings Limited
  • Merck Sharp & Dohme Corp.

第13章 附錄

目錄
Product Code: IRTNTR30751

About this market

Technological advances in diagnostics to drive market growth. The diagnostic methods that are currently available in the market include Pap test, colposcopy, and HPV DNA test. Pap test is a screening procedure for cervical cancer, in which the presence of precancerous or cancerous cells is identified on the cervix. Colposcopy is a more advanced technique like a Pap test, which allows the examiner to take abnormal cell tissues from the cervix. Technavio's analysts have predicted that the human papillomavirus (HPV) therapeutics market will register a CAGR of nearly 9% by 2023.

Market Overview

Advent of vaccines

The global HPV therapeutics market witnessed strong advances in terms of prevention of diseases caused by HPV. This is primarily due to the increasing research on developing highly advanced vaccines with a longer half-life. Vaccines were proved to have strong efficacy toward the prevention of various disease-causing viruses and highly effective toward the prevention of various indications caused by HPV.

Multiple-dose schedules of vaccines

Despite the availability of vaccines for the prevention of indications caused by HPV, the market faces a challenge from their recurring doses. As the vaccines that are currently approved for HPV are developed for administering through invasive methods such as subcutaneous route, the need for multiple doses affects the patient adherence toward the completion of the dose cycle.

For the detailed list of factors that will drive and challenge the growth of the human papillomavirus (HPV) therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including ALLERGAN and Bausch Health the competitive environment is quite intense. Factors such as the advent of vaccines and the technological advances in diagnostics, will provide considerable growth opportunities to human papillomavirus (HPV) manufactures. ALLERGAN, Bausch Health, GlaxoSmithKline, Lee's Pharmaceutical Holdings, and Merck Sharp & Dohme are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY ROA

  • Market segmentation by RoA
  • Comparison by RoA
  • Parenteral - Market size and forecast 2018-2023
  • Topical - Market size and forecast 2018-2023
  • Market opportunity by RoA

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ALLERGAN
  • Bausch Health
  • GlaxoSmithKline plc.
  • Lee's Pharmaceutical Holdings Limited
  • Merck Sharp & Dohme Corp.

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: RoA - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by RoA
  • Exhibit 20: Parenteral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Parenteral - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Topical - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Topical - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by RoA
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Key leading countries
  • Exhibit 37: Market opportunity
  • Exhibit 38: Decision framework
  • Exhibit 39: Impact of drivers and challenges
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: ALLERGAN - Vendor overview
  • Exhibit 46: ALLERGAN - Product segments
  • Exhibit 47: ALLERGAN - Organizational developments
  • Exhibit 48: ALLERGAN - Geographic focus
  • Exhibit 49: ALLERGAN - Segment focus
  • Exhibit 50: ALLERGAN - Key offerings
  • Exhibit 51: ALLERGAN - Key customers
  • Exhibit 52: Bausch Health - Vendor overview
  • Exhibit 53: Bausch Health - Product segments
  • Exhibit 54: Bausch Health - Organizational developments
  • Exhibit 55: Bausch Health - Geographic focus
  • Exhibit 56: Bausch Health - Segment focus
  • Exhibit 57: Bausch Health - Key offerings
  • Exhibit 58: Bausch Health - Key customers
  • Exhibit 59: GlaxoSmithKline plc. - Vendor overview
  • Exhibit 60: GlaxoSmithKline plc. - Business segments
  • Exhibit 61: GlaxoSmithKline plc. - Organizational developments
  • Exhibit 62: GlaxoSmithKline plc. - Geographic focus
  • Exhibit 63: GlaxoSmithKline plc. - Segment focus
  • Exhibit 64: GlaxoSmithKline plc. - Key offerings
  • Exhibit 65: GlaxoSmithKline plc. - Key customers
  • Exhibit 66: Lee's Pharmaceutical Holdings Limited - Vendor overview
  • Exhibit 67: Lee's Pharmaceutical Holdings Limited - Business segments
  • Exhibit 68: Lee's Pharmaceutical Holdings Limited - Organizational developments
  • Exhibit 69: Lee's Pharmaceutical Holdings Limited - Segment focus
  • Exhibit 70: Lee's Pharmaceutical Holdings Limited - Key offerings
  • Exhibit 71: Lee's Pharmaceutical Holdings Limited - Key customers
  • Exhibit 72: Merck Sharp & Dohme Corp. - Vendor overview
  • Exhibit 73: Merck Sharp & Dohme Corp. - Business segments
  • Exhibit 74: Merck Sharp & Dohme Corp. - Organizational developments
  • Exhibit 75: Merck Sharp & Dohme Corp. - Geographic focus
  • Exhibit 76: Merck Sharp & Dohme Corp. - Segment focus
  • Exhibit 77: Merck Sharp & Dohme Corp. - Key offerings
  • Exhibit 78: Merck Sharp & Dohme Corp. - Key customers
  • Exhibit 79: Validation techniques employed for market sizing
  • Exhibit 80: List of abbreviations
Back to Top